← Back to Search

mTOR Inhibitor

PTX-022 for Pachyonychia Congenita

Phase 3

Recruiting

Research Sponsored by Palvella Therapeutics, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 6 months

Awards & highlights

Study Summary

This trial studies if a drug can be safely used to treat a rare skin condition called Pachyonychia Congenita (PC). The drug, QTORIN rapamycin 3.9% anhydrous gel, is being tested to see if it's safe to use for longterm treatment.

Eligible Conditions

Pachyonychia Congenita

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 6 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~6 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Treatment emergent adverse events

Secondary outcome measures

Pharmacokinetic parameters

Trial Design

1Treatment groups

Experimental Treatment

Group I: PTX-022Experimental Treatment1 Intervention

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Palvella Therapeutics, Inc.Lead Sponsor

6 Previous Clinical Trials

314 Total Patients Enrolled

3 Trials studying Pachyonychia Congenita

189 Patients Enrolled for Pachyonychia Congenita

Media Library

PTX-022 (mTOR Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT05643872 — Phase 3

Pachyonychia Congenita Research Study Groups: PTX-022

Pachyonychia Congenita Clinical Trial 2023: PTX-022 Highlights & Side Effects. Trial Name: NCT05643872 — Phase 3

PTX-022 (mTOR Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05643872 — Phase 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any opportunities still available to participate in this research?

"According to the details found on clinicaltrials.gov, this study is seeking enrolment from interested patients. The project was initially published on November 15th 2022 and underwent an update shortly thereafter in December 1st of that same year."

Answered by AI

What potential risks does PTX-022 pose to those who use it?

"Our team at Power ranks the safety of PTX-022 as a 3, implying that there is ample evidence to support its efficacy and several trials have been conducted which demonstrate its security."

Answered by AI

How many individuals are being recruited for this research endeavor?

"Absolutely. According to clinicaltrials.gov, this research endeavor was initially posted on November 15th 2022 and is now recruiting participants. 45 patients need to be sourced from one single medical centre for the trial's completion."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Study Evaluating the Safety and Pharmacokinetics of QTORIN Rapamycin 3.9% Anhydrous Gel in the Treatment of Adults With Pachyonychia Congenita

2022. "A Study Evaluating the Safety and Pharmacokinetics of QTORIN Rapamycin 3.9% Anhydrous Gel in the Treatment of Adults With Pachyonychia Congenita". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05643872.

All > Pachyonychia Congenita